Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-12 8:17 pm Purchase |
2020-12-31 | 13G | F-star Therapeutics, Inc. FSTX |
BIOTECHNOLOGY VALUE FUND L P | 25,844 1.000% |
25,844 (New Position) |
Filing History |
| 2021-02-12 8:16 pm Purchase |
2020-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
BIOTECHNOLOGY VALUE FUND L P | 2,768,278 9.990% |
739,873 (+36.48%) |
Filing History |
| 2021-02-12 7:58 pm Sale |
2020-12-31 | 13G | Therapeutics Acquisition Corp. RACA |
BIOTECHNOLOGY VALUE FUND L P | 954,996 6.800% |
-45,004 (-4.50%) |
Filing History |
| 2021-02-12 7:23 pm Purchase |
2020-12-31 | 13G | Regulus Therapeutics Inc. RGLS |
BIOTECHNOLOGY VALUE FUND L P | 705,046 9.990% |
495,376 (+236.26%) |
Filing History |
| 2021-02-12 6:52 pm Sale |
2020-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
BIOTECHNOLOGY VALUE FUND L P | 3,499,346 10.000% |
-17,505 (-0.50%) |
Filing History |
| 2021-02-12 6:47 pm Purchase |
2020-12-31 | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS |
BIOTECHNOLOGY VALUE FUND L P | 1,814,308 9.980% |
1,814,308 (New Position) |
Filing History |
| 2021-02-12 5:16 pm Purchase |
2020-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BIOTECHNOLOGY VALUE FUND L P | 3,710,689 7.400% |
894,299 (+31.75%) |
Filing History |
| 2021-02-12 5:03 pm Purchase |
2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA |
BIOTECHNOLOGY VALUE FUND L P | 5,285,549 9.990% |
2,123,881 (+67.18%) |
Filing History |
| 2021-02-12 4:25 pm Sale |
2020-12-31 | 13G | Sutro Biopharma, Inc. STRO |
BIOTECHNOLOGY VALUE FUND L P | 1,854,162 4.100% |
-514,230 (-21.71%) |
Filing History |
| 2021-02-12 4:22 pm Purchase |
2020-12-31 | 13G | Repare Therapeutics Inc. RPTX |
BIOTECHNOLOGY VALUE FUND L P | 2,972,191 8.100% |
1,027,645 (+52.85%) |
Filing History |
| 2021-02-12 4:20 pm Sale |
2020-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
BIOTECHNOLOGY VALUE FUND L P | 70,020 9.990% |
-3,390 (-4.62%) |
Filing History |
| 2021-02-12 4:18 pm Sale |
2020-12-31 | 13G | Ovid Therapeutics Inc. OVID |
BIOTECHNOLOGY VALUE FUND L P | 4,522,051 6.900% |
-733,250 (-13.95%) |
Filing History |
| 2021-02-12 4:16 pm Purchase |
2020-12-31 | 13G | Merus N.V. MRUS |
BIOTECHNOLOGY VALUE FUND L P | 5,805,571 19.960% |
815,000 (+16.33%) |
Filing History |
| 2021-02-12 4:15 pm Sale |
2020-12-31 | 13G | Kezar Life Sciences, Inc. KZR |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-203,979 (Position Closed) |
Filing History |
| 2021-02-12 4:13 pm Sale |
2020-12-31 | 13G | Galmed Pharmaceuticals Ltd. GLMD |
BIOTECHNOLOGY VALUE FUND L P | 9,998 8.400% |
-182 (-1.79%) |
Filing History |
| 2021-02-12 4:11 pm Purchase |
2020-12-31 | 13G | Forte Biosciences, Inc. FBRX |
BIOTECHNOLOGY VALUE FUND L P | 53,770 9.990% |
10,171 (+23.33%) |
Filing History |
| 2021-02-12 4:09 pm Sale |
2020-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
BIOTECHNOLOGY VALUE FUND L P | 2,898,797 9.990% |
-22,380 (-0.77%) |
Filing History |
| 2021-02-12 4:06 pm Purchase |
2020-12-31 | 13G | Cidara Therapeutics, Inc. CDTX |
BIOTECHNOLOGY VALUE FUND L P | 223,075 9.990% |
54,637 (+32.44%) |
Filing History |
| 2021-02-11 5:29 pm Sale |
2020-12-31 | 13G | MEI Pharma, Inc. MEIP |
BIOTECHNOLOGY VALUE FUND L P | 279,466 4.900% |
-64,856 (-18.84%) |
Filing History |
| 2021-02-11 5:27 pm Purchase |
2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 5,576,471 12.100% |
950,060 (+20.54%) |
Filing History |